Viewing Study NCT02926833


Ignite Creation Date: 2025-12-25 @ 2:41 AM
Ignite Modification Date: 2026-06-02 @ 12:53 AM
Study NCT ID: NCT02926833
Status: COMPLETED
Last Update Posted: 2024-03-06
First Post: 2016-10-05
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Sponsor: Kite, A Gilead Company
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Refractory Diffuse Large B Cell Lymphoma View
Keywords: